Lyell Immunopharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Lyell Immunopharma Inc: Is Infosys Ltd. worth buying?
Item: Lyell Immunopharma Inc
Rating: 1.79491675
Author: Trendlyne DVM scores

about

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

12.82 -0.48 (-3.61%)

59.94% Fall from 52W High

32,402

XNAS Volume

XNAS 12 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

14.2 / 100

Technically Neutral

57.6 / 100

1Yr Price target downside is -14%

2 analysts

Lyell Immunopharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Lyell Immunopharma Inc Live Stock Price Today, Share Analysis and Chart

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

59.94% Fall from 52W High

SWOT Analysis

Lyell Immunopharma Inc Live Price Chart